Delcath Systems Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Gerard Michel

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi	21.3%
CEO görev süresi	4yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors

Sep 10

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Aug 27

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 07

CEO Tazminat Analizi

Gerard Michel'un ücretlendirmesi Delcath Systems'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$3m	US$538k	-US$48m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$34m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$521k	-US$37m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$2m	US$475k	-US$26m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$6m	US$113k	-US$24m

Tazminat ve Piyasa: Gerard 'nin toplam tazminatı ($USD 2.52M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).

Tazminat ve Kazançlar: Gerard şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Gerard Michel (61 yo)

4yrs

Görev süresi

US$2,520,314

Tazminat

Mr. Gerard J. Michel, MS, MBA, serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020. He had been Chief Financial Officer and Vice President of Corporate Development a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerard Michel	CEO & Director	4yrs	US$2.52m	1.14% $ 3.3m
Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer	1.3yrs	Veri yok	0.22% $ 633.7k
Martha Rook	Chief Operating Officer	less than a year	Veri yok	Veri yok
David Hoffman	General Counsel	2.8yrs	Veri yok	0.27% $ 771.6k
Johnny John	Senior Vice President of Clinical Operations & Medical Affairs	3.8yrs	US$737.50k	Veri yok
Vojislav Vukovic	Chief Medical Officer	1.3yrs	Veri yok	0.45% $ 1.3m

2.0yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: DCTH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerard Michel	CEO & Director	4yrs	US$2.52m	1.14% $ 3.3m
Elizabeth Czerepak	Independent Director	4.7yrs	US$188.51k	0% $ 0
Steven Salamon	Independent Director	4.4yrs	US$183.96k	0.29% $ 853.2k
John Sylvester	Independent Chairman	5.3yrs	US$204.88k	0.038% $ 109.5k
Gilad Aharon	Independent Director	4.4yrs	US$172.96k	0.11% $ 320.6k
Bridget Martell	Director	less than a year	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DCTH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Delcath Systems Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & Director exercised options to buy US$177k worth of stock.

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Executive Changes

CEO & Director recently bought US$100k worth of stock

Recent updates

CEO & Director exercised options to buy US$177k worth of stock.

Forecast breakeven date moved forward to 2025

Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors

Consensus EPS estimates fall by 14%

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?

Consensus revenue estimates increase by 13%

Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Delcath Systems Regains Compliance with the Audit Committee Composition Requirements

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 11%

Price target increased by 8.1% to US$20.80

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind